-
Mashup Score: 1SWOG - 2 year(s) ago
SWOG Model Results Predict Risk of Early Death in Patients With AMLAn international team has developed statistical models to predict the risk of early death in patients being treated with non-intensive therapies for acute myeloid leukemia (AML). Results of analyses using the models were presented at the 2021 American Society of Hematology (ASH) Annual Meeting on…
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Dr. Agarwal explains SWOG S1216 results for TAK-700 in mHSPC - 3 year(s) ago
Neeraj Agarwal, MD, discusses results from the phase 3 SWOG S1216 trial, which compared ADT plus the novel agent TAK-700 or bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Dr. Agarwal explains SWOG S1216 results for TAK-700 in mHSPC https://t.co/v8NPzfPeFI #prostatecancer #pcsm #urology #urologist #SWOG
-
-
Mashup Score: 2
ASCO GU 2021 Genitourinary Cancers Symposium, Sunitinib Versus Cabozantinib, Crizotinib or Savolitinib in Metastatic Papillary Renal Cell Carcinoma (pRCC): Results from the Randomized Phase II SWOG 1500 Study.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Sunitinib vs cabozantinib, crizotinib, or savolitinib in metastatic papillary #RenalCellCarcinoma: results from the randomized phase II #SWOG 1500 study. Presented by @montypal @cityofhope. #GU21 session summary by @WallisCJD @VUMCurology > https://t.co/zUYL44QarD @ASCO #ASCOGU https://t.co/2KQX6E0ZFC
-
-
Mashup Score: 0Sumanta (Monty) K. Pal, MD @montypal @cityofhope #ASCOG - 3 year(s) ago
Sumanta (Monty) K. Pal, MD of the City of Hope speaks about A randomized, multi-arm comparison of targeted therapies for advanced papillary renal cell carc
Source: www.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A randomized, multi-arm comparison of targeted therapies for advanced PRCC Sumanta (Monty) K. Pal, MD @montypal @cityofhope #ASCOGU21 #SWOG #KidneyCancer #Cancer #Research Link To FULL Video: https://t.co/3yTTXQhWbm https://t.co/SpqbN214fn
-
-
Mashup Score: 0
Some postmenopausal women with HR-positive, HER2-negative breast cancer may not benefit from chemotherapy and can safely forgo the treatment, according to results from a randomized clinical trial presented at the San Antonio Breast Cancer Symposium. The finding may spare many women unnecessary treatments.
Source: National Cancer InstituteCategories: Hem/Oncs, Latest HeadlinesTweet-
S1007: Postmenopausal women with ER+ breast cancer, 1-3 lymph nodes, and low-med Recurrence Score may forgo chemotherapy #sabcs20 #swog https://t.co/pixNBeWM2S
-
-
Mashup Score: 0SWOG Board of Governors - The Hope Foundation - 4 year(s) ago
Funding provided for the travel of current members of the SWOG Board of Governors in order to facilitate participation at Group Meetings.
Source: The Hope FoundationCategories: Hem/Oncs, Latest HeadlinesTweet-
Board of Governors @SWOG @SupportingSWOG funding provided for the travel of current members of the #SWOG #BoardofGovernors in order to facilitate participation in the SWOG BOG and Group Meeting this fall—Fall 2020 deadline: August 26 #NCTN #HopeFoundation https://t.co/rMVwjEMWu0
-
-
Mashup Score: 0Submit a 2021 Program Proposal - The Hope Foundation - 4 year(s) ago
Proposal Form for 2020 Hope Foundation Programs Supporting SWOG Cancer Research Network.
Source: The Hope FoundationCategories: Hem/Oncs, Latest HeadlinesTweet-
#Funding #opportunity! Now through August 1, @SupportingSWOG @SWOG members are encouraged to submit ideas for improving all aspects of their #cancer #research #network #SWOGonc #NCTN #TheHopeFoundation #ForCancerResearch #SWOG https://t.co/vABLTKwZLT
-
-
Mashup Score: 0
Simple, modern video meetings for everyone on the world’s most popular and trusted collaboration platform.
Source: Cisco Webex SiteCategories: Hem/Oncs, Latest HeadlinesTweet-
Best of @SWOG at @ASCO #webinar on Friday, July 10 at 2 pm PT—Hear from: @recnac1 @SWOGChair @karenkellymd @fischmd @lynnhenrymd @szusmani @KenGrossmannMD @IshwariaMD @pcvblack @SupportingSWOG #ASCO20 #MedEd #BestofSWOGatASCO #SWOG Register at https://t.co/QFaRGJRXQg
-
-
Mashup Score: 5ASCO 2020: Baseline CTC Count as a Prognostic Marker of PSA Response and Progression in mCSPC: Results from Phase III SWOG S1216 - 4 year(s) ago
asco 2020 biomarkers predicting clinical outcomes for androgen receptor signaling inhibition, SWOG 1216 clinical trial, CELLSEARCH® CTC biomarker for mcspc patients, CTC counts in an analysis of data from SWOG S1216, CTC counts as prognostic factor in mCSPC
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet-
Baseline CTC count as a prognostic marker of #PSA response and progression in #mCSPC: results from phase III #SWOG S1216. Presentation by Amir Goldkorn, MD @KeckMedUSC. #ASCO20 coverage by @zklaassen_md @GACancerCenter > https://t.co/QS0iK6Jcne @ASCO @SWOG @neerajaiims https://t.co/RpfsNOuxWp
-
-
Mashup Score: 2
PURPOSE Despite reported widespread use of dietary supplements during cancer treatment, few empirical data with regard to their safety or efficacy exist. Because of concerns that some supplements, particularly antioxidants, could reduce the cytotoxicity of chemotherapy, we conducted a prospective study ancillary to a therapeutic trial to evaluate associations between supplement use and breast…
Source: Journal of Clinical OncologyCategories: Hem/OncsTweet-
#swog #Oncoalert Dietary Supplement Use During Chemotherapy in a Cooperative Group Clinical Trial (SWOG S0221) https://t.co/Jowseg1bm1 @swog @oncoalert @nicolekuderer @fredhutch uwdeptmedicine Antioxidant/supplement use during breast ca chemotherapy requires caution.
-
#ASH21: SWOG Model Results Predict Risk of Early Death in Patients With #AML: https://t.co/2Bt3T8m58f #HemOnc #AMLNews #SWOG https://t.co/THf6nk7k83